Search
Mitoguazone
go.drugbank.com/drugs/DB12967InvestigationalMitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalAs of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnThese are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
HPA-23
go.drugbank.com/drugs/DB17739ExperimentalHPA-23 is an investigational antiviral compound.[A259142]
3,5-diiodothyropropionic acid
go.drugbank.com/drugs/DB12629InvestigationalDITPA has been investigated in Congestive Heart Failure.
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalIt is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].
BBM-H803
go.drugbank.com/drugs/DB17700InvestigationalIt consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781InvestigationalHu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated
Escin
go.drugbank.com/drugs/DB15907Investigationalprognosis in massive cerebral infarction) and NCT05263167 (aimed at reducing edema after intracerebral hemorrhage). … Sodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and